- Home
- BDRX vs SCNI Comparison
BDRX vs SCNI Comparison
Compare BDRX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- SCNI
- Stock Information
- Founded
- BDRX 2000
- SCNI 2003
- Country
- BDRX United Kingdom
- SCNI Israel
- Employees
- BDRX N/A
- SCNI N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDRX Health Care
- SCNI Health Care
- Exchange
- BDRX Nasdaq
- SCNI Nasdaq
- Market Cap
- BDRX 3.9M
- SCNI 4.6M
- IPO Year
- BDRX N/A
- SCNI N/A
- Fundamental
- Price
- BDRX $6.80
- SCNI $1.44
- Analyst Decision
- BDRX
- SCNI
- Analyst Count
- BDRX 0
- SCNI 0
- Target Price
- BDRX N/A
- SCNI N/A
- AVG Volume (30 Days)
- BDRX 350.4K
- SCNI 103.4K
- Earning Date
- BDRX 09-12-2025
- SCNI 11-21-2025
- Dividend Yield
- BDRX N/A
- SCNI N/A
- EPS Growth
- BDRX N/A
- SCNI N/A
- EPS
- BDRX N/A
- SCNI 0.26
- Revenue
- BDRX N/A
- SCNI $1,147,000.00
- Revenue This Year
- BDRX N/A
- SCNI N/A
- Revenue Next Year
- BDRX N/A
- SCNI N/A
- P/E Ratio
- BDRX N/A
- SCNI $5.27
- Revenue Growth
- BDRX N/A
- SCNI 303.87
- 52 Week Low
- BDRX $5.00
- SCNI $1.20
- 52 Week High
- BDRX $92.00
- SCNI $6.18
- Technical
- Relative Strength Index (RSI)
- BDRX 46.19
- SCNI 49.76
- Support Level
- BDRX $7.21
- SCNI $1.32
- Resistance Level
- BDRX $7.71
- SCNI $1.53
- Average True Range (ATR)
- BDRX 1.00
- SCNI 0.11
- MACD
- BDRX -0.21
- SCNI 0.01
- Stochastic Oscillator
- BDRX 8.47
- SCNI 39.00
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.